Calidi Biotherapeutics, Inc. (CLDI)
1.12
+0.02
(+1.82%)
USD |
NYAM |
Sep 21, 16:00
1.18
+0.06
(+5.36%)
After-Hours: 20:00
Calidi Biotherapeutics Enterprise Value : -0.0571M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | -0.0571M |
| September 17, 2026 | 0.2969M |
| September 16, 2026 | 0.0886M |
| September 15, 2026 | 0.0886M |
| September 14, 2026 | 0.1928M |
| September 11, 2026 | 0.2344M |
| September 10, 2026 | 0.3802M |
| September 09, 2026 | 0.4843M |
| September 08, 2026 | 0.4635M |
| September 04, 2026 | 0.5364M |
| September 03, 2026 | 0.4635M |
| September 02, 2026 | 0.4427M |
| September 01, 2026 | 0.4219M |
| August 31, 2026 | 0.4427M |
| August 28, 2026 | 0.401M |
| August 27, 2026 | 0.3594M |
| August 26, 2026 | 0.4635M |
| August 25, 2026 | 0.3802M |
| August 24, 2026 | 0.526M |
| August 21, 2026 | 0.4427M |
| August 20, 2026 | 0.4427M |
| August 19, 2026 | 0.526M |
| August 18, 2026 | 0.2969M |
| August 17, 2026 | 0.4843M |
| August 14, 2026 | 0.9633M |
| Date | Value |
|---|---|
| August 13, 2026 | 0.8592M |
| August 12, 2026 | 1.047M |
| August 11, 2026 | 1.068M |
| August 10, 2026 | 1.047M |
| August 07, 2026 | 1.026M |
| August 06, 2026 | 1.380M |
| August 05, 2026 | 1.317M |
| August 04, 2026 | 1.588M |
| August 03, 2026 | 1.151M |
| July 31, 2026 | 1.068M |
| July 30, 2026 | 0.7609M |
| July 29, 2026 | 0.7609M |
| July 28, 2026 | 1.231M |
| July 27, 2026 | 1.301M |
| July 24, 2026 | 0.9842M |
| July 23, 2026 | 1.151M |
| July 22, 2026 | 1.171M |
| July 21, 2026 | 0.9675M |
| July 20, 2026 | 1.504M |
| July 17, 2026 | 1.614M |
| July 16, 2026 | 1.504M |
| July 15, 2026 | 1.747M |
| July 14, 2026 | 1.717M |
| July 13, 2026 | 2.074M |
| July 10, 2026 | 2.347M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
| Anixa Biosciences, Inc. | 80.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.16M |
| Total Expenses (Quarterly) | 4.16M |
| EPS Diluted (Quarterly) | -2.938 |
| Earnings Yield | -4.83K% |
| Normalized Earnings Yield | -4824.07 |